2024 – Page 189 – Talk Bio

Actionable Insights Powered by AI

Landmark Federal Data Privacy Proposal Unveiled

1 year ago talkbio0Tagged Consumer, federal, Privacy, proposal - intent, public showcase, rights, Rules of conduct

Federal Data Privacy, Public Showcase, Proposal, Consumer Rights, Privacy Law

Vertex’s Acquisition of Alpine Immune Sciences for Povetacicept: Humira-like Potential in IgAN, but Indication Variations Matter

1 year ago talkbio0Tagged ALPN-303, Humira-like potential, IGA Glomerulonephritis, multiple autoimmune diseases, Povetacicept

Vertex, Alpine Immune Sciences, Povetacicept (ALPN-303), IgA nephropathy (IgAN), Humira-like potential, Multiple autoimmune diseases

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce

1 year ago talkbio0Tagged Acorda, Biological Factors, Biopharma layoffs, Cara, Eiger, Fujifilm, Genomic Orientation, Invitae, Pfizer, sanofi, Vedanta

Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer

Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development

1 year ago1 year ago talkbio0Tagged Biotechnology, BMS, Bristol Myers Squibb, checkpoint inhibitor, Drug Development, GPR65 gene, Immunotherapy for cancer, Investments, Pathios

Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.

Vertex Initiates FDA Rolling Review for Non-Opioid Pain Medication Suzetrigine (VX-548)

1 year ago talkbio0Tagged Acute onset pain, Non-opioid painkiller, Rolling Review, Suzetrigine, United States Food and Drug Administration, VX-548

Vertex Pharmaceuticals, Suzetrigine (VX-548), Non-opioid painkiller, FDA rolling review, Acute pain

Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo

1 year ago talkbio0Tagged Eli Lilly, Metsera, Novo, Obesity, Phase I injectable, Product containing glucagon-like peptide 1 receptor agonist (product)

Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)

Cerevel Reports Phase 3 Parkinson’s Study Success Amidst AbbVie Acquisition

1 year ago talkbio0Tagged AbbVie Acquisition, Cerevel, Clinical Trials, Parkinson 's disease trial, Phase 3, Tavapadon

Cerevel Therapeutics, Phase 3 Parkinson’s disease trial, Tavapadon, AbbVie acquisition, Successful clinical trial results

Biotech Company Raises $54M to Dominate Dendritic Cell-Amplifying Vaccines Market

1 year ago talkbio0Tagged APEX1 protein, human, biotech, cornering, dendritic cell-amplifying vaccines, Immune response, Market, Regulators (device)

Biotech, $54M funding, Dendritic cell-amplifying vaccines, Market cornering, Immune response, Apex regulators

23andMe Stock Surges as CEO Considers Taking Company Private

1 year ago talkbio0Tagged CEO, Privatization Plans, Science of genetics, Stock Jump

23andMe, Stock Jump, CEO, Privatization Plans, Genetics Company